Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | MC3R | P41968 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132527 | 0.90 | SIRT6 (0.41) | SIRT6OPRM1OPRD1OPRK1ADORA3 | |
| SCHEMBL6470756 | 0.82 | MEN1 (0.40) | F2ALDH1A1 | |
| SCHEMBL6468945 | 0.81 | SIRT6 (0.42) | SIRT6OPRM1OPRK1ADORA3TSHR | |
| SCHEMBL6468982 | 0.79 | SIRT6 (0.41) | SIRT6OPRM1OPRD1OPRK1ADORA3 | |
| SCHEMBL6468944 | 0.78 | SIRT6 (0.44) | SIRT6OPRM1OPRD1OPRK1ADORA3 | |
| SCHEMBL30874231 | 0.75 | SIRT6 (0.49) | SIRT6OPRM1OPRD1OPRK1ADORA3 | |
| SCHEMBL30483004 | 0.72 | SIRT6 (0.49) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL5134062 | 0.71 | OPRM1 (0.52) | SIRT6OPRM1OPRD1OPRK1 | |
| SCHEMBL6469048 | 0.69 | KDM4E (0.46) | — | |
| SCHEMBL5132531 | 0.69 | MEN1 (0.42) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | SIRT6 750/4885OPRM1 1245/4885OPRD1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.